Assisted reproductive technology – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Assisted reproductive technology – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on GnRH Agonists for Ovulation and Luteal Support in IVF Patients: Comparing GnRH Agonist with hCG and Progesterone https://clinicaltrials.eu/trial/study-on-gnrh-agonists-for-ovulation-and-luteal-support-in-ivf-patients-comparing-gnrh-agonist-with-hcg-and-progesterone/ Wed, 29 Apr 2026 14:26:30 +0000 https://clinicaltrials.eu/trial/study-on-gnrh-agonists-for-ovulation-and-luteal-support-in-ivf-patients-comparing-gnrh-agonist-with-hcg-and-progesterone/ This clinical trial is focused on studying treatments for individuals undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), which are methods used to help with conception. The study is comparing two different approaches to support the luteal phase, which is a part of the menstrual cycle that occurs after ovulation. The first approach uses a medication called a GnRH agonist to trigger ovulation and support the luteal phase. The second approach, which is the current standard, uses a hormone called hCG to trigger ovulation and supports the luteal phase with progesterone administered vaginally.

The purpose of the study is to see if using the GnRH agonist alone can increase the chances of a live birth compared to the standard method. Participants in the study will receive one of these treatments and will be monitored throughout their IVF or ICSI cycle. The study will track various outcomes, including the rate of live births, the success of embryo implantation, and the occurrence of any pregnancy-related conditions. The medications involved in the study include progesterone, follitropin beta, follitropin alfa, ganirelix, nafarelin, triptorelin, choriogonadotropin alfa, and cetrorelix.

Participants will be given these medications in various forms, such as injections or nasal sprays, depending on the specific treatment protocol they are assigned to. The study aims to provide valuable information on the effectiveness and safety of these treatments in improving the chances of a successful pregnancy and live birth for individuals undergoing IVF or ICSI. The trial will continue until 2027, with the goal of gathering comprehensive data to inform future fertility treatments.

]]>